Noninferiority (NI) phase III trials in oncology: What is the basis for choosing the NI margin?

被引：0
|
作者：
Militao, M. S. [1 ]
Saad, E. D. [1 ]
机构：
[1] Dendrix Res, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e13070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13070
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Visualizing the Landscape of Selection Biomarkers in Current Phase III Oncology Clinical Trials
    Sikorski, Robert
    Yao, Bin
    SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (34)
  • [22] Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
    Beck, Esther J.
    Sherry, Alexander D.
    Florez, Marcus A.
    Kouzy, Ramez
    Jaoude, Joseph Abi
    Lin, Timothy A.
    Miller, Avital M.
    Passy, Adina H.
    Kupferman, Gabrielle S.
    Patel, Roshal R.
    Chino, Fumiko
    Higbie, Victoria Serpas
    Parseghian, Christine M.
    Overman, Michael J.
    Minsky, Bruce D.
    Thomas, Charles R.
    Tang, Chad
    Msaouel, Pavlos
    Ludmir, Ethan B.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 2183 - 2188
  • [23] Phase III Radiation Oncology Clinical Trials: A Snapshot of the Last Two Decades
    Kouzy, R.
    Jaoude, J. Abi
    El Alam, M. B.
    Mainwaring, W.
    Lin, T. A.
    Miller, A. B.
    Jethanandani, A.
    Espinoza, A. F.
    Ludmir, E. B.
    Taniguchi, C. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E788 - E789
  • [24] Speed of Accrual Into Phase III Oncology Trials A Comparison Across Geographic Locations
    Ruther, Nancy R.
    Mathiason, Michelle A.
    Wee, Sandra K.
    Emmel, Ann E.
    Go, Ronald S.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (06): : 575 - 582
  • [25] The era of geriatric oncology: Phase II/III trials over the decades.
    Sui, Jane Sze Yin
    Teo, MinYuen
    Sui, Jacklyn Sze Tin
    Picardo, Sarah Louise
    O'Riordan, Lynda M.
    McCarthy, Michael Thomas
    Kelly, Deirdre
    McCaffrey, John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Inference failure with synthetic arms: Empirical application to phase III oncology trials
    Decruyenaere, A.
    Dehaene, H.
    Rabaey, P.
    Polet, C.
    Decruyenaere, J.
    Demeester, T.
    Vansteelandt, S.
    Rottey, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S526 - S527
  • [27] Comparison of futility monitoring guidelines using completed phase III oncology trials
    Zhang, Qiang
    Freidlin, Boris
    Korn, Edward L.
    Halabi, Susan
    Mandrekar, Sumithra
    Dignam, James J.
    CLINICAL TRIALS, 2017, 14 (01) : 48 - 58
  • [28] Treatment group-specific inferences in Phase III Randomized Oncology Trials
    Sherry, Alexander D.
    Passy, Adina H.
    Jaoude, Joseph Abi
    Lin, Timothy A.
    Kouzy, Ramez
    Msaouel, Pavlos
    Ludmir, Ethan B.
    ACTA ONCOLOGICA, 2025, 64 : 470 - 474
  • [29] Who Needs What? Perceptions of Patients and Caregivers in Oncology Phase 1 Trials
    Rezash, Victoria
    Reed, Janice
    Gedeon, Barbara
    Parsons, Eric
    Siedlecki, Sandra
    Daniels, Bradley
    Shepard, Dale R.
    JOURNAL OF PATIENT EXPERIENCE, 2020, 7 (01): : 27 - 33
  • [30] Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?
    Udayakumar, Suji
    Thomson, Sasha
    Razak, Albiruni R. Abdul
    Chan, Kelvin K. W.
    TARGETED ONCOLOGY, 2022, 17 (06) : 665 - 674
12345